Comparative Pharmacology
Head-to-head clinical analysis: AMABELZ versus LEVORA 0 15 30 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMABELZ versus LEVORA 0 15 30 28.
AMABELZ vs LEVORA 0.15/30-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMABELZ (amenamevir) is a helicase-primase inhibitor that inhibits the viral DNA replication by targeting the helicase-primase complex (UL5/UL52) of herpes simplex virus (HSV) and varicella-zoster virus (VZV).
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Also induces changes in cervical mucus (increasing viscosity) and endometrium (reducing receptivity) to impair sperm penetration and implantation.
100 mg orally once daily.
One tablet orally once daily at the same time each day for 28 days (21 active tablets containing 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, followed by 7 placebo tablets).
None Documented
None Documented
Terminal half-life of 4-6 hours; clinically relevant for dosing interval of 8-12 hours in normal renal function.
Ethinyl estradiol: 13-27 hours (terminal); Levonorgestrel: 11-45 hours (terminal, dose-dependent due to SHBG binding).
Primarily renal (70-80% unchanged), with minor biliary/fecal elimination (10-15%).
Renal: ~50% (as glucuronide and sulfate conjugates of ethinyl estradiol and levonorgestrel); Fecal: ~50% (enterohepatic recirculation).
Category C
Category C
Oral Contraceptive
Oral Contraceptive